|
| Exchange Disseminated Time | Marksans Pharma Ltd has informed BSE that the members at the 19th Annual General Meeting (AGM) of the Company held on September 29, 2011, inter alia, have transacted the following:
1. Adoption of the Audited Balance Sheet as at March 31, 2011, the Profit and Loss Account for the period ended March 31, 2011 and the Reports of the Directors’ and the Auditors’ thereon.
2. Appointment of Mr. M. B. Parikh, as a Director of the Company, liable to retire by rotation.
3. Appointment of M/s. N. K. Mittal and Associates, Chartered Accountants, as Auditors of the Company to hold office from the conclusion of this Annual General Meeting till the conclusion of the next Annual General Meeting on remuneration, terms & conditions.
4. Appointment of Dr. Balwant Shankarrao Desai, as a Director of the Company liable to retire by rotation.
5. Appointment of Dr. Balwant Shankarrao Desai, as Whole Time Director (Quality & Regulatory Affairs) of the Company for a period of three (3) years with effect from September 29, 2011 on remuneration, terms & conditions.
6. Authority to the Board to create, offer, issue and allot, from time to time, in one or more tranches, upto 1,75,00,000 (One Crore Seventy Five Lacs only) Warrants on a preferential basis to Mr. Mark Saldanha and/or other Promoters and/or Promoter Group of the Company, entitling the holder of each Warrant, from time to time, to apply for and obtain allotment of one equity share of the face value of Re. 1/- each against such Warrant (hereinafter referred to as the Warrants), in one or more tranches, in such manner and on such price, terms and conditions as may be determined by the Board in accordance with the ICDR Regulations or other provisions of law as may be prevailing at the time, provided that the minimum price of the Warrants so issued shall not be less than the price arrived at in accordance with the provisions of Chapter VII of ICDR Regulations. |
|
|